Covidien Gains Barrett’s Esophagus Ablation Device Via Barrx Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Deal worth $325 million bolsters Covidien’s energy-based product offerings with Barrx Medical’s radiofrequency energy-based HaloFlex system for preventing esophageal cancer.
You may also be interested in...
Covidien Ventures Into Capsule-Based Endoscopy With Given Imaging Acquisition
The $860 million purchase agreement will give Covidien the dominant capsule endoscopy platform on the market as the company hopes for FDA approval this year of PillCam COLON 2 as a less invasive alternative for patients who are unable to undergo a colonoscopy.
Covidien Buys superDimension: $300 Mil. Deal Targets Lung Cancer Screening Market
Acquired iLogic system includes planning and navigation software that generates three-dimensional images using patient CT scans, and disposable catheter-based tools for navigation and biopsy.
Covidien Plans April U.S. Launch Of Solitaire For Ischemic Strokes
Clot removal device gains 510(k) clearance earlier than expected, will compete with Stryker’s Merci clot retrieval system.